A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
出版年份 2023 全文链接
标题
A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
作者
关键词
-
出版物
Pharmaceuticals
Volume 16, Issue 7, Pages 934
出版商
MDPI AG
发表日期
2023-06-28
DOI
10.3390/ph16070934
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review
- (2023) Bianca Raffaelli et al. CEPHALALGIA
- Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study
- (2023) Guerzoni Simona et al. ACTA NEUROLOGICA BELGICA
- Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202)
- (2023) Sait Ashina et al. CEPHALALGIA
- Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
- (2023) Andreas A. Argyriou et al. EUROPEAN JOURNAL OF NEUROLOGY
- An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor
- (2023) Francesca Schiano di Cola et al. EUROPEAN JOURNAL OF NEUROLOGY
- Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study
- (2023) Hyoung Cheol Lee et al. NEUROLOGICAL SCIENCES
- Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
- (2023) Lucas Hendrik Overeem et al. Frontiers in Neurology
- Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
- (2022) Vincent Martin et al. CLINICAL THERAPEUTICS
- Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
- (2022) Luigi Francesco Iannone et al. CNS DRUGS
- Trigeminal sensory modulatory effects of galcanezumab and clinical response prediction
- (2022) Kuan-Po Peng et al. PAIN
- Migraine
- (2022) Michel D. Ferrari et al. Nature Reviews Disease Primers
- Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients
- (2022) Soonwook Kwon et al. CEPHALALGIA
- Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
- (2022) Patricia Pozo-Rosich et al. CURRENT MEDICAL RESEARCH AND OPINION
- Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
- (2022) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
- (2022) Maurice T. Driessen et al. JOURNAL OF HEADACHE AND PAIN
- Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study
- (2022) Christopher Kjaer Cullum et al. JOURNAL OF HEADACHE AND PAIN
- Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
- (2022) Magdalena Nowaczewska et al. Frontiers in Neurology
- The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
- (2022) Mária Dux et al. Cells
- Salivary CGRP and erenumab treatment response: towards precision medicine in migraine
- (2022) Alicia Alpuente et al. ANNALS OF NEUROLOGY
- Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
- (2022) Michael Lowe et al. JOURNAL OF HEADACHE AND PAIN
- The ultimate guide to the anti-CGRP monoclonal antibodies galaxy
- (2022) Davide Mascarella et al. NEUROLOGICAL SCIENCES
- Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study
- (2022) Ilaria Cetta et al. NEUROLOGICAL SCIENCES
- Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention
- (2022) Carlo Lovati et al. NEUROLOGICAL SCIENCES
- Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review
- (2022) Ann M. Murray et al. Current Pain and Headache Reports
- Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy : The multicenter prospective cohort GARLIT study
- (2022) Fabrizio Vernieri et al. EUROPEAN JOURNAL OF NEUROLOGY
- Serum CGRP in migraine patients using erenumab as preventive treatment
- (2022) Simone de Vries Lentsch et al. JOURNAL OF HEADACHE AND PAIN
- Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
- (2022) Piero Barbanti et al. JOURNAL OF HEADACHE AND PAIN
- Cranial autonomic symptoms and response to monoclonal antibodies targeting the Calcitonin gene-related peptide pathway: A real-world study
- (2022) Eleonora De Matteis et al. Frontiers in Neurology
- Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
- (2022) Tsubasa Takizawa et al. BMC Neurology
- A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home
- (2022) Koichi Hirata et al. Expert Opinion On Drug Safety
- Association between response to triptans and response to erenumab: real-life data
- (2021) Ilaria Frattale et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
- (2021) Egilius L. H. Spierings et al. JOURNAL OF HEADACHE AND PAIN
- The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
- (2021) Marta Torres-Ferrús et al. JOURNAL OF NEUROLOGY
- Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
- (2021) Raffaele Ornello et al. Brain Sciences
- Refractory migraine profile in CGRP‐monoclonal antibodies scenario
- (2021) Marcello Silvestro et al. ACTA NEUROLOGICA SCANDINAVICA
- Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
- (2021) Uwe Reuter et al. ADVANCES IN THERAPY
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study
- (2021) Takao Takeshima et al. HEADACHE
- Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache
- (2021) Umberto Pensato et al. NEUROLOGICAL SCIENCES
- Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series
- (2021) María Del Pilar Briceño-Casado et al. European Journal of Hospital Pharmacy-Science and Practice
- Predictors of response to erenumab after 12 months of treatment
- (2021) Carlo Baraldi et al. Brain and Behavior
- Effectiveness and Safety of CGRP-mAbs in Menstrual-Related Migraine: A Real-World Experience
- (2021) Marcello Silvestro et al. Pain and Therapy
- Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study
- (2021) Fumihiko Sakai et al. DRUG SAFETY
- Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
- (2021) Fabrizio Vernieri et al. EUROPEAN JOURNAL OF NEUROLOGY
- Clinic and genetic predictors in response to erenumab
- (2021) Chiara Zecca et al. EUROPEAN JOURNAL OF NEUROLOGY
- Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
- (2021) Edoardo Caronna et al. JOURNAL OF HEADACHE AND PAIN
- Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
- (2021) Sara Bottiroli et al. JOURNAL OF HEADACHE AND PAIN
- CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
- (2021) Fenne Vandervorst et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
- (2021) Jean Schoenen et al. Frontiers in Neurology
- Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
- (2021) Raffaele Ornello et al. Frontiers in Neurology
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting
- (2020) Anne-Sophie Wattiez et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of erenumab in women with a history of menstrual migraine
- (2020) Jelena M. Pavlovic et al. JOURNAL OF HEADACHE AND PAIN
- Vascular actions of peripheral CGRP in migraine-like photophobia in mice
- (2020) Bianca N Mason et al. CEPHALALGIA
- Erenumab in Chronic Migraine: An Australian Experience
- (2020) Shuli Cheng et al. HEADACHE
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
- (2020) Danuta Szkutnik-Fiedler Pharmaceutics
- Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
- (2019) Messoud Ashina et al. CEPHALALGIA
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Migraine
- (2019) Rebecca C. Burch et al. NEUROLOGIC CLINICS
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CGRP as the target of new migraine therapies — successful translation from bench to clinic
- (2018) Lars Edvinsson et al. Nature Reviews Neurology
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
- (2018) Andrea C. Tricco et al. ANNALS OF INTERNAL MEDICINE
- Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
- (2018) Stefanie Förderreuther et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic migraine: risk factors, mechanisms and treatment
- (2016) Arne May et al. Nature Reviews Neurology
- Validation of the Patient Health Questionnaire-9 (PHQ-9) and PHQ-2 in patients with migraine
- (2015) Jong-Geun Seo et al. JOURNAL OF HEADACHE AND PAIN
- Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine
- (2015) Jong-Geun Seo et al. JOURNAL OF HEADACHE AND PAIN
- Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine
- (2015) R. B. Lipton et al. NEUROLOGY
- A confirmatory bifactor analysis of the hospital anxiety and depression scale in an Italian community sample
- (2014) Luca Iani et al. Health and Quality of Life Outcomes
- Depression and risk of transformation of episodic to chronic migraine
- (2012) Sait Ashina et al. JOURNAL OF HEADACHE AND PAIN
- Psychiatric comorbidities of episodic and chronic migraine
- (2012) Dawn C. Buse et al. JOURNAL OF NEUROLOGY
- Calcitonin gene-related peptide: A molecular link between obesity and migraine?
- (2010) A. Recober et al. DRUG NEWS & PERSPECTIVES
- CGRP and its receptors provide new insights into migraine pathophysiology
- (2010) Tony W. Ho et al. Nature Reviews Neurology
- EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force
- (2009) S. Evers et al. EUROPEAN JOURNAL OF NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now